Opthea Limited Investor Relations Material

Opthea Limited is a clinical-stage biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative therapies primarily for eye diseases. The company's primary focus is on advancing its intellectual property portfolio, which encompasses Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3. These are aimed to be used in treating diseases associated with blood and lymphatic vessel growth as well as vascular leakage. The company is headquartered in South Yarra, Victoria, Australia, and its shares are listed on the NASDAQ and ASX.